Additionally, we detected the CYP1A1 editing levels in 34 matched primary NSCLC and normal adjacent tissues (NATs) from individuals within our cohort, revealing that approximately 61.8% (21/34 patients) of the primary NSCLC specimens exhibited CYP1A1 overediting as defined by an increase of not less than 10% editing in tumors compared with in adjacent nontumor specimens (Fig. 1C). This evidence concerns the gene CYP1A1 and non-small cell lung carcinoma.